Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis

NCT02452866 is registered in ClinicalTrials.gov with Symbiomix Therapeutics as lead sponsor.

NCT NCT02452866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis
Lead sponsor
Symbiomix Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
October 31, 2015
Enrollment
325 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial vaginosis